ImmunityNCT02244372
Efficacy and Safety of Cordyceps Sinensis Mycelium Culture Extract(Paecilomyces Hepiali, CBG-CS-2) on Promotion of Immunity
A study testing Cordyceps sinensis mycelium culture extract 0.76 g and Cordyceps sinensis mycelium culture extract 1.15 g in people with Immunity, run by Chonbuk National University Hospital at 1 site in South Korea.
Trial summary
The investigators performed randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of Cordyceps sinensis mycelium culture extract (Paecilomyces hepiali, CBG-CS-2) on promotion of immunity. Read more about this study
- Who is it for?
- Ages 20 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Immunity
- What is being tested?
- Cordyceps sinensis mycelium culture extract 0.76 g and Cordyceps sinensis mycelium culture extract 1.15 g
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 90 participants
- Where
- 1 siteSouth Korea
- Study dates
- Sep 2014to Feb 2015
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 80 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Males and females 20-80 years old
- Who had suffered more than twice Upper respiratory infection* disorder or common cold causing URI
- Able to give informed consent
Who cannot join
- WBC concentration below 3000 ㎕
- Subjects vaccinated against influenza within the last 6 months prior to the study
- Subjects with Upper respiratory infection at screening visit
- Subjects with BMI < 18.5 kg/m2 at screening visit
- Allergic or hypersensitive to any of the ingredients in the test products
- Diagnosed of gastrointestinal disease such as Immune-related diseases, severe hepatic, renal failure, and diabetes
Show all 11Show fewer
- History of reaction to any of the test products or of gastrointestinal diseases such as Crohn's disease or gastrointestinal surgery
- History of alcohol or substance abuse
- Participation in any other clinical trials within past 2 months
- Laboratory test, medical or psychological conditions deemed by the investigators to interfere with successful participation in the study
- Pregnant or lactating women etc.
Trial locations and contacts
1 site in 1 country.
South Korea1 site
Clinical Trial Center for Functional Foods; Chonbuk National University Hospital
Jeonju, Jeollabuk-do, 560-822
About this study
Official title: A 8-week, Randomized, Double-blind, Placebo-controlled Human Trial to Evaluate the Efficacy and Safety of Cordyceps Sinensis Mycelium Culture Extract(Paecilomyces Hepiali, CBG-CS-2) on Promotion of Immunity
The investigators performed randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of Cordyceps sinensis mycelium culture extract (Paecilomyces hepiali, CBG-CS-2) on promotion of immunity. The investigators measured promotion of immunity parameters , including Cytotoxicity, Cytokine (IL-4, IL-6, IL-12, IFN-γ, TNF-α), hs-CRP, antibody titer, and upper respiratory tract infection(URI)
- Conditions
- Immunity
- Being tested
- Cordyceps sinensis mycelium culture extract 0.76 g, Cordyceps sinensis mycelium culture extract 1.15 g, Placebo
- Keywords
- Cordyceps sinensis mycelium culture extract(Paecilomyces hepiali, CBG-CS-2), immunity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cordyceps sinensis mycelium culture extract 0.76 gDietary supplement
Cordyceps sinensis mycelium culture extract 1.15 gDietary supplement
PlaceboDietary supplement
| Study group | Role | What they receive |
|---|---|---|
| Cordyceps sinensis mycelium culture extract 0.76 g | Experimental | Cordyceps sinensis mycelium culture extract 0.76 g Receives: Dietary Supplement: Cordyceps sinensis mycelium culture extract 0.76 g |
| Cordyceps sinensis mycelium culture extract 1.15 g | Experimental | Cordyceps sinensis mycelium culture extract 1.15 g Receives: Dietary Supplement: Cordyceps sinensis mycelium culture extract 1.15 g |
| Placebo | Placebo comparator | Placebo Receives: Dietary Supplement: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes in Cytotoxicity
Cytotoxicity was measured in study visit 1(0 week), visit 2(4 week) and visit 3(8 week). cytotoxicity was measured by NK cell activity.
Cytotoxicity (%) = (experimental release - spontaneous release) / (maximum release - spontaneous release) x 100
Measured: 4, 8 weeks
Secondary outcomes (2)
Changes in Cytokine(IL-4, IL-6, IL-12, IFN-γ, TNF-α)
Cytokine(IL-4, IL-6, IL-12, IFN-γ, TNF-α) was measured in study visit 1(0 week), visit 2(4 week), and visit 3(8 week).
Measured: 4, 8 weeks
Changes in hs-CRP
hs-CRP was measured in study visit 1(0 week), visit 2(4 week) and visit 3(8 week).
Measured: 4, 8 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Sep 2014 (estimated)
- Study startSep 2014
- Primary completionSep 2014
- Study completionFeb 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ImmunityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 90 participants (actual)
Sponsor and investigators
- Lead sponsor
- Chonbuk National University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Soo-Wan Chae, Chonbuk National University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02244372
- Sponsor's protocol ID
- CHE-PI-CM
- Status last verified
- Aug 2019
- First submitted
- 17 Sep 2014
- Last updated
- 22 Aug 2019
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 22 Aug 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A 8-week, Randomized, Double-blind, Placebo-controlled Human Trial to Evaluate the Efficacy and Safety of Cordyceps Sinensis Mycelium Culture Extract(Paecilomyces Hepiali, CBG-CS-2) on Promotion of Immunity
- ClinicalTrials.gov ID
- NCT02244372
- Acronym / sponsor ID
- CHE-PI-CM
- Conditions
- Immunity
- Keywords
- Cordyceps sinensis mycelium culture extract(Paecilomyces hepiali, CBG-CS-2), immunity
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 90 participants (actual)
- Lead sponsor
- Chonbuk National University HospitalUniversity, hospital or other
- Study start
- Sep 2014
- Primary completion
- Sep 2014 (actual)
- Study completion
- Feb 2015 (actual)
- First posted
- 19 Sep 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The investigators performed randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of Cordyceps sinensis mycelium culture extract (Paecilomyces hepiali, CBG-CS-2) on promotion of immunity. The investigators measured promotion of immunity parameters , including Cytotoxicity, Cytokine (IL-4, IL-6, IL-12, IFN-γ, TNF-α), hs-CRP, antibody titer, and upper respiratory tract infection(URI)
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Cordyceps sinensis mycelium culture extract 0.76 g | Experimental | Dietary Supplement: Cordyceps sinensis mycelium culture extract 0.76 gCordyceps sinensis mycelium culture extract 0.76 g |
| Cordyceps sinensis mycelium culture extract 1.15 g | Experimental | Dietary Supplement: Cordyceps sinensis mycelium culture extract 1.15 gCordyceps sinensis mycelium culture extract 1.15 g |
| Placebo | Placebo comparator | Dietary Supplement: PlaceboPlacebo |
Who may qualify
- Ages
- 20 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Males and females 20-80 years old
- Who had suffered more than twice Upper respiratory infection* disorder or common cold causing URI
- Able to give informed consent
Key exclusion criteria (11 listed)
- WBC concentration below 3000 ㎕
- Subjects vaccinated against influenza within the last 6 months prior to the study
- Subjects with Upper respiratory infection at screening visit
- Subjects with BMI < 18.5 kg/m2 at screening visit
- Allergic or hypersensitive to any of the ingredients in the test products
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cordyceps sinensis mycelium culture extract 0.76 g | Dietary supplement | Cordyceps sinensis mycelium culture extract 0.76 g |
| Cordyceps sinensis mycelium culture extract 1.15 g | Dietary supplement | Cordyceps sinensis mycelium culture extract 1.15 g |
| Placebo | Dietary supplement | Placebo |
Primary outcome
Changes in Cytotoxicity
Time frame: 4, 8 weeks
Cytotoxicity was measured in study visit 1(0 week), visit 2(4 week) and visit 3(8 week). cytotoxicity was measured by NK cell activity. Cytotoxicity (%) = (experimental release - spontaneous release) / (maximum release - spontaneous release) x 100
2 secondary outcomes
Changes in Cytokine(IL-4, IL-6, IL-12, IFN-γ, TNF-α)
Time frame: 4, 8 weeks
Changes in hs-CRP
Time frame: 4, 8 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Aug 2019.
Related trials for Immunity
Active, not recruitingPhase 4
Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
Immunization, HPV Infection
Not yet recruitingObservational study
Characterization of Adaptive Immune Responses to Oropouche Virus (OROV) Infection
Oropouche Infection
Active, not recruitingPhase 4
Thymosin Alpha 1 and IgM Levels in Sepsis
Sepsis, Septic Shock
Recruiting
Effects of Different Activation Techniques on Antimicrobial Photodynamic Therapy in Apical Periodontitis
Apical Periodontitis, Endodontic Retreatment
Active, not recruitingEarly Phase 1
Vaccine Pandemic Preparedness Through Airway Immunology Characterization
Influenza, Human
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Cordyceps sinensis mycelium culture extract 0.76 g and Cordyceps sinensis mycelium culture extract 1.15 g in people with Immunity, run by Chonbuk National University Hospital at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Aug 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Changes in Cytotoxicity (time frame: 4, 8 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Aug 2019.